Medical Products Supplies Companies

2722 Loker Ave West Suite G, 92010 Carlsbad, CA
USA
Telephone +1 619 733-7386
info@newlifediagnostics.com
http://www.newlifediagnostics.com

Product Categories

Product categories

03 Diagnostic Tests
03.05 Infectious immunology testing
03.05.02 Microbiological diagnosis, virology, equipment and systems for

Microbiological diagnosis, virology, equipment and systems for

Dengue IgG Microwell Serum ELISA Catalog# DEN-G (Export Only)
Leptospira IgG/IgM Microwell Serum ELISA Catalog# LEPTO-G/M (Export Only)
Leishmania Microwell Serum ELISA Catalog# LEISH-96 (Export Only)

Our products

Product category: Microbiological diagnosis, virology, equipment and systems for
Dengue IgG Microwell Serum ELISA Catalog# DEN-G (Export Only)
Dengue fever, caused by any of the four serotypes of dengue virus, is endemic in Southeast Asia as well as South and Central America. Repeat infection with a second type of dengue virus is thought to cause dengue hemorrhagic fever in about 10 percent of infected people. Dengue antibodies do not confer immunity beyond 3-6 weeks to a second dengue type. Epidemiological factors, clinical findings (including fever, tachycardia, thrombocytopenia, etc.), exposure in endemic regions, and other laboratory results should be considered in diagnosing acute disease. Acute disease diagnosis will also include a positive laboratory confirmation in many cases. Infection with dengue virus can result in a wide disease spectrum, from a mild fever to life-threatening dengue hemorrhagic fever and dengue shock syndrome.1 Symptoms of classical dengue fever, following a 5-8 day incubation period, include rash, severe headache, nausea, vomiting, chills, malaise, macular rash and may include lymphadenopathy. Hemorrhagic dengue fever involves increased blood vessel permeability which can lead to shock and death in about 10% of reported cases. Dengue fever can only be treated by supportive care and is prevented by mosquito control. In primary infections, circulating IgM antibody to the viral coat proteins is detected 5-6 days after the onset of illness, and gradually decreases within 1-2 months of onset. IgG antibody to dengue virus is detected approximately 14 days after onset in primary infections, and by day 2 in secondary infections. In secondary infections, IgM antibody may reappear but gradually diminishes, while IgG antibody persists, often at high titer. These patterns of dengue antibody development permit serological differentiation of primary and secondary infections. Characteristically, acute patients with primary infections have a higher IgM:IgG ratio than are found in secondary infections. Patients with secondary infections generally have higher IgG levels. Acute or recent infections are identified by a rise in antibody titer as well as high IgM levels. The Flaviviridae family includes the four serotypes of dengue virus as well as the yellow fever and Japanese encephalitis viruses. There is substantial cross reactivity among flaviviruses, due to the presence of common antigenic determinants. The four dengue serotypes cross react among themselves, but there are also unique determinants for each serotype. Although infection with a given serotype confers durable protection against that serotype, dengue virus serotypes are not cross-protective, and reinfection with a second serotype has been linked to development of the more severe hemorrhagic form of dengue referred to as dengue hemorrhagic fever. Determination of the infecting serotype may be important in gauging the potential severity of a dengue outbreak.1 The most straightforward diagnosis of a recent infection is achieved by detection of the virus in patient’s blood, either by isolating the virus in susceptible cell cultures or mosquitoes, or by identifying viral RNA with hybridization6 or PCR8 techniques. However, these methods are laborious and require specialized laboratory facilities. In addition, the level of circulating virus wanes as the antibody level rises, and these procedures are successful only when done within about 5 days of onset of illness. Serological methods to detect dengue antibodies have been the most commonly used diagnostic procedures. The ELISA microwell method for the detection of IgM antibodies is currently the most useful procedure for providing a specific serological diagnosis of dengue infection. This method is reported to be as sensitive as the Hemagglutination Inhibition (HI) method.7 The IgM ELISA method is generally replacing other techniques for IgM determination because of its sensitivity, potential for automation and ability to accommodate large numbers of samples. For the determination of IgM antibody by the ELISA method, it has been recommended that measures be taken to eliminate IgG antibodies from current or previous flavivirus infections, since IgG antibodies may be present in excess and depress the sensitivity for the detection of IgM.

Product category: Microbiological diagnosis, virology, equipment and systems for
Leptospira IgG/IgM Microwell Serum ELISA Catalog# LEPTO-G/M (Export Only)
The clinical manifestations of leptospirosis range from a mild catarrh-like illness to icteric disease with severe liver and kidney involvement. Natural reservoirs for leptospirosis include rodents as well as a large variety of domesticated mammals. The organisms occupy the lumen of nephritic tubules in their natural host and are shed into the urine. Human infection derives from direct exposure to infected animals (veterinarians, abattoir workers, or dairy workers for example) or by exposure to environments contaminated by animal carriers (e.g. agricultural workers). Bathing or swimming in water sources about which livestock have been pastured has been demonstrated to be a potential infection hazard. The organisms enter the host through skin abrasions, mucosal surfaces or the eye. The incubation period can range from 3 to 30 days but is usually found to be 10 to 12 days. Antibodies can become detectable by the 6th to 10th day of disease and generally reach peak levels within 3 to 4 weeks. Antibody levels then gradually recede but may remain detectable for years.
Epidemiologic factors, clinical findings, exposure in endemic regions, and other laboratory results should be considered in diagnosing acute disease. Acute disease diagnosis will also include a positive laboratory confirmation in many cases. This test is designed to measure acute infections with leptospira. Confirmation of a positive sample by additional methods should be followed.

Product category: Microbiological diagnosis, virology, equipment and systems for
Leishmania Microwell Serum ELISA Catalog# LEISH-96 (Export Only)
Visceral Leishmaniasis (VL) is a severe disease with high mortality, caused by parasite members of the L. donovani complex (1,2). The vector for transmission is the sand fly, whose carriers of infection are typically dogs (3-6). It is a disease endemic to many countries and is a serious problem in many developing nations, particularly with the increasing urbanization of populations (7). High incidence is encountered in parts of Latin America, East Africa, Middle East, India and China. It is endemic to countries bordering the Mediterranean such as Italy, Southern France, Spain, Portugal, and Northern Africa. In Southern Europe, VL has become the leading opportunistic infection in AIDS patients (8-15).
Diagnosis of acute VL is often attempted by aspiration of bone marrow for direct parasite identification. The procedure is invasive, painful, dangerous and has a low success rate due to the inability to always isolate parasites from the tissue. Alternatively, serodiagnosis is widely utilized since anti-leishmanial antibody titers are typically high during the acute disease phase. ELISA is the preferred laboratory test for serodiagnosis of VL, although indirect immunofluorescent antibody tests (IFAT) and direct agglutination tests (DAT), using whole parasites, are still widely used in conjunction with ELISA or alone (16-18).

ad: contact information

About Us

Company details
Who is New Life Diagnostics

A qualified team of professionals with over thirty years of experience in the development, manufacture, and marketing of high performance immunoassays.

The Source

New Life is THE ORIGINAL developer and manufacturer of all of its products. COME TO THE SOURCE!

A Trusted Partner

The facility is an FDA Registered Device Manufacturer operating under cGMP’s and excelling at lot to lot reproducibility. Accurate, consistent,quality products and service are delivered every time. Products are also CE Marked for free sale throughout Europe.

We’re about you

Clients are demanding more functionality and better results from their diagnostic testing, and we are committed to producing high quality results. Our passion is helping our clients build solutions that strike the perfect balance between service, precision, and technology.

ad: company